News und Analysen
EQS-News: MPH Health Care AG veröffentlicht Geschäftszahlen für Q1/2026
EQS-News: MPH Health Care AG veröffentlicht Geschäftszahlen für Q1/2026
Amneal Pharmaceuticals Bets on Biosimilars, Patches to Power Next Growth Phase
Key Points
- Interested in Amneal Pharmaceuticals, Inc.? Here are five stocks we like better.
- Amneal Pharmaceuticals says it is entering a stronger growth phase, helped by unexpectedly solid
The Bank of Mom and Dad Is Booming—3 Stocks to Watch
Key Points
- Interested in Extra Space Storage Inc? Here are five stocks we like better.
- Rising financial dependence on parents is creating investment opportunities across storage, healthcare, and
Contentstack stellt seine „Agentic Experience Platform“ (AXP) mit „Agent OS“ und „Agent Accelerator“ vor, um Hindernisse für den ROI und die Einführung von KI in Unternehmen zu beseitigen
Die Agentic Experience Platform schafft ein geregeltes Ökosystem, das Marken, Inhalte und Kontext miteinander verbindet, und bietet Unternehmen, die den Schritt von KI-Experimenten hin zu operativen
Nvidia Aktie: RTX Spark mit Microsoft
Nvidia wird nicht mehr nur daran gemessen, ob der nächste Rechenzentrum-Zyklus heiß bleibt. Die…
Der Beitrag Nvidia Aktie: RTX Spark mit Microsoft erschien zuerst auf kapitalmarktexperten.de.
Quelle
Amgen Eyes 2026 ‘Springboard’ as Growth Drugs Offset Patent Pressure
Key Points
- Interested in Amgen Inc.? Here are five stocks we like better.
- Amgen said its strong first-quarter results support the idea that 2026 could be a “springboard year”, with revenue up
CareDx Sharpens Precision Diagnostics Push With Naveris Deal, AlloHeme Plans
Key Points
- Interested in CareDx, Inc.? Here are five stocks we like better.
- CareDx is pivoting deeper into precision diagnostics by divesting its lab products unit and using the proceeds to
Bioventus Highlights PNS, PRP Growth as Cash Flow Improves and Debt Falls
Key Points
- Interested in Bioventus Inc.? Here are five stocks we like better.
- Bioventus said its financial profile has improved materially, with EBITDA margins rising above 20% in 2025, free
Vail Resorts Q3 Earnings Call Highlights
Key Points
- Interested in Vail Resorts, Inc.? Here are five stocks we like better.
- Severe weather across the Western U.S., especially in the Rockies, hurt Vail Resorts’ fiscal third-quarter
FuelCell Energy Q2 Earnings Call Highlights
Key Points
- Interested in FuelCell Energy, Inc.? Here are five stocks we like better.
- FuelCell Energy reported a wider fiscal Q2 loss after a $42.6 million non-cash impairment tied to its Groton
CG Oncology Touts Cretostimogene Data, BLA Progress in Bladder Cancer Push
Key Points
- Interested in CG Oncology, Inc.? Here are five stocks we like better.
- CG Oncology said its lead bladder cancer therapy, cretostimogene, has shown encouraging efficacy in
CareDx Highlights 39% Q1 Growth, Naveris Oncology Push at Jefferies
Key Points
- Interested in CareDx, Inc.? Here are five stocks we like better.
- CareDx posted strong Q1 results, with revenue up 39% year over year and Testing Services volume up 17%. The company
Bruker Signals Growth Pivot as Semiconductor and Overseas Orders Gain Steam
Key Points
- Interested in Bruker Corporation? Here are five stocks we like better.
- Order momentum is improving across Bruker’s business, with semiconductor metrology, overseas
BioAge Labs Eyes Key BGE-102 Readouts in Heart Risk and Diabetic Eye Disease
Key Points
- Interested in BioAge Labs, Inc.? Here are five stocks we like better.
- BioAge Labs said its lead drug BGE-102 is on track for near-term data in two areas: a Phase 2 cardiovascular
Gerresheimer Aktie: Goldman erhöht auf 20,03 Prozent
Goldman Sachs baut bei Gerresheimer weiter auf. Die US-Investmentbank hält nun 20,03 Prozent der…
Der Beitrag Gerresheimer Aktie: Goldman erhöht auf 20,03 Prozent erschien zuerst auf kapitalmarktexp
Black Diamond Therapeutics Touts Silevertinib Lung Cancer Data, Eyes FDA Path
Key Points
- Interested in Black Diamond Therapeutics, Inc.? Here are five stocks we like better.
- Silevertinib showed encouraging Phase 2 lung cancer data, including a 60% objective response
Bayer Aktie: 7,25-Mrd.-Vergleich am 9. Juli
35,95 Euro – das ist der Stand der Dinge bei Bayer zum Ende der…
Der Beitrag Bayer Aktie: 7,25-Mrd.-Vergleich am 9. Juli erschien zuerst auf kapitalmarktexperten.de.
Quelle kapitalmarktexperten.de
BioCryst Pharmaceuticals Backs ORLADEYO Outlook as Navenibart Trial Advances
Key Points
- Interested in BioCryst Pharmaceuticals, Inc.? Here are five stocks we like better.
- BioCryst reaffirmed full-year ORLADEYO revenue guidance of $625 million to $645 million and
Axsome Therapeutics Readies Auvelity Alzheimer’s Agitation Launch, Expands CNS Pipeline
Key Points
- Interested in Axsome Therapeutics, Inc.? Here are five stocks we like better.
- Axsome Therapeutics said it is on track to launch Auvelity for Alzheimer’s disease agitation this
Arrowhead Pharmaceuticals Lines Up SHASTA Readout as REDEMPLO Launch Gains Traction
Key Points
- Interested in Arrowhead Pharmaceuticals, Inc.? Here are five stocks we like better.
- SHASTA-3 and SHASTA-4 topline data for plozasiran in severe hypertriglyceridemia remain on track
argenx Touts VYVGART Growth, 50,000-Patient Goal at William Blair Conference
Key Points
- Interested in argenex SE? Here are five stocks we like better.
- argenx said its main priorities are revenue growth, profitability and execution as it expands the VYVGART franchise
Amgen Touts MariTide, AI Gains and 2026 Growth Plans at Jefferies Conference
Key Points
- Interested in Amgen Inc.? Here are five stocks we like better.
- Amgen highlighted strong first-quarter performance, with revenue up 6% year over year and non-GAAP EPS up 5%
Aldeyra Therapeutics Eyes FDA Feedback as Dry Eye Drug Faces Make-or-Break Moment
Key Points
- Interested in Aldeyra Therapeutics, Inc.? Here are five stocks we like better.
- Aldeyra Therapeutics is awaiting near-term FDA feedback on its dry eye drug reproxalap after a third
Akebia Therapeutics Sees Vafseo Uptake Rising as Access and Pipeline Milestones Near
Key Points
- Interested in Akebia Therapeutics, Inc.? Here are five stocks we like better.
- Vafseo uptake is improving, with Akebia saying the number of prescribing physicians rose 28% to about
Aclaris Therapeutics Maps Busy Pipeline Calendar, Plans Phase 2 Asthma Trial for ATI-052
Key Points
- Interested in Aclaris Therapeutics, Inc.? Here are five stocks we like better.
- Aclaris Therapeutics is preparing a packed clinical calendar, with data expected in the second half of